Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-25-015744
Filing Date
2025-04-25
Accepted
2025-04-25 16:15:48
Documents
20
Period of Report
2025-05-23

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20042463x2_def14a.htm   iXBRL DEF 14A 1772009
3 GRAPHIC logo_nektar.jpg GRAPHIC 14135
4 GRAPHIC ny20042463x2_barchart01.jpg GRAPHIC 173557
5 GRAPHIC ny20042463x2_pvpchart01.jpg GRAPHIC 212153
6 GRAPHIC ny20042463x2_pvpchart02.jpg GRAPHIC 176356
7 GRAPHIC ny20042463x2_pc01.jpg GRAPHIC 732188
8 GRAPHIC ny20042463x2_pc02.jpg GRAPHIC 590759
  Complete submission text file 0001140361-25-015744.txt   7726036

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION - SCHEMA nktr-20250523.xsd EX-101.SCH 2129
23 EXTRACTED XBRL INSTANCE DOCUMENT ny20042463x2_def14a_htm.xml XML 330093
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-24006 | Film No.: 25874258
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)